US Stock MarketDetailed Quotes
ATNM Actinium
- 1.760
- +0.050+2.92%
Close Nov 4 16:00 ET
- 1.799
- +0.039+2.21%
Post 16:18 ET
54.83MMarket Cap-1165P/E (TTM)
1.760High1.690Low158.84KVolume1.710Open1.710Pre Close273.38KTurnover0.52%Turnover RatioLossP/E (Static)31.15MShares10.24052wk High1.25P/B53.45MFloat Cap1.33052wk Low--Dividend TTM30.37MShs Float450.000Historical High--Div YieldTTM4.09%Amplitude1.330Historical Low1.721Avg Price1Lot Size
About Actinium Company
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
Company Profile
SymbolATNM
Company NameActinium
Listing DateMar 26, 2014
Founded2000
CEOMr. Sandesh Seth
MarketAMEX
Employees49
Fiscal Year Ends12-31
Address100 Park Avenue,23rd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10017
Phone1-646-677-3870
Company Executives
- Name
- Position
- Salary
- Sandesh Seth
- Chairman of the Board and Chief Executive Officer
- 4.02M
- Steve O’Loughlin
- Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
- 1.48M
- Dr. Jeffrey W. Chell, M.D.
- Independent Director
- 301.75K
- Richard I. Steinhart
- Independent Director
- 313.75K
- Dr. David Nicholson, Pd.D
- Lead Independent Director
- 313.75K
- Dr. Ajit S. Shetty, PhD
- Independent Director
- 309.25K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data